Login
$CGEM
$9.51 -$0.77 (7.49%) Live

$CGEM SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren’s disease will be shared in December

10 Nov 2026 SCHEDULE 13G
09 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026

06 Nov 2026 Form 4: Michaelson Jennifer, Chief Scientific Officer

Received 3,805 shares by exercise or conversion ($16.4K) · Sold 4,000 shares ($49.4K)

05 Nov 2026 144
04 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

02 Oct 2026 8-K: Regulation FD Disclosure; Other Events

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

24 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November

14 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

10 Sep 2026 Form 4: Michaelson Jennifer, Chief Scientific Officer

Received 4,000 shares by exercise or conversion ($17.2K) · Sold 8,000 shares ($173K)

08 Sep 2026 144
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 Form 4: Michaelson Jennifer, Chief Scientific Officer

Received 30,000 shares by exercise or conversion ($129K) · Sold 30,000 shares ($608K)

14 Aug 2026 SCHEDULE 13G
13 Aug 2026 144
13 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

07 Aug 2026 SCHEDULE 13G
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support